Toronto – October 12, 2026 -- Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) will report its second quarter 2026 financial results after market close on Thursday, August 6, 2026.
Management hosts call at 4:30 p.m. ET on results day
The interventional MRI (iMRI) company will hold a conference call at 4:30 p.m. ET on August 6 to review the quarter's results and discuss business developments in the period. Investors must register in advance for the live call.
Two MRI-guided platforms drive the commercial portfolio
Profound markets TULSA-PRO, which is FDA-cleared in the United States for transurethral ultrasound ablation (TULSA) of prostate tissue. The system is also cleared in Europe, Canada, Saudi Arabia, India, Australia/New Zealand and the UAE.
The company's second product, Sonalleve, holds FDA approval as a Humanitarian Device Exemption (HDE) in the United States for treating osteoid osteomas in the extremities. Sonalleve is also cleared or approved in Europe, Canada, China and Saudi Arabia.
Live broadcast and archive available on investor site
The call will be broadcast live and archived in the Investors section of the company's website. The release did not include financial guidance or preliminary figures for the quarter.